The effects of medicare advantage on opioid use
Author
Abstract
Suggested Citation
DOI: 10.1016/j.jhealeco.2019.102278
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Christopher C. Afendulis & Michael E. Chernew & Daniel P. Kessler, 2017. "The Effect of Medicare Advantage on Hospital Admissions and Mortality," American Journal of Health Economics, University of Chicago Press, vol. 3(2), pages 254-279, Spring.
- Molly Schnell & Janet Currie, 2018.
"Addressing the Opioid Epidemic: Is There a Role for Physician Education?,"
American Journal of Health Economics, MIT Press, vol. 4(3), pages 383-410, Summer.
- Molly Schnell & Janet Currie, 2018. "Addressing the Opioid Epidemic: Is There a Role for Physician Education?," American Journal of Health Economics, University of Chicago Press, vol. 4(3), pages 383-410, Summer.
- Molly Schnell & Janet Currie, 2017. "Addressing the Opioid Epidemic: Is There a Role for Physician Education?," NBER Working Papers 23645, National Bureau of Economic Research, Inc.
- Chernew, Michael & DeCicca, Philip & Town, Robert, 2008.
"Managed care and medical expenditures of Medicare beneficiaries,"
Journal of Health Economics, Elsevier, vol. 27(6), pages 1451-1461, December.
- Michael Chernew & Philip DeCicca & Robert Town, 2008. "Managed Care and Medical Expenditures of Medicare Beneficiaries," NBER Working Papers 13747, National Bureau of Economic Research, Inc.
- Duggan, Mark & Starc, Amanda & Vabson, Boris, 2016.
"Who benefits when the government pays more? Pass-through in the Medicare Advantage program,"
Journal of Public Economics, Elsevier, vol. 141(C), pages 50-67.
- Mark Duggan & Amanda Starc & Boris Vabson, 2014. "Who Benefits when the Government Pays More? Pass-Through in the Medicare Advantage Program," NBER Working Papers 19989, National Bureau of Economic Research, Inc.
- Mark Duggan & Amanda Starc & Boris Vabson, 2014. "Who Benefits when the Government Pays More? Pass-Through in the Medicare Advantage Program," Discussion Papers 14-004, Stanford Institute for Economic Policy Research.
- Baker, Laurence C., 1997. "The effect of HMOs on fee-for-service health care expenditures: Evidence from Medicare," Journal of Health Economics, Elsevier, vol. 16(4), pages 453-481, August.
- Marika Cabral & Michael Geruso & Neale Mahoney, 2018.
"Do Larger Health Insurance Subsidies Benefit Patients or Producers? Evidence from Medicare Advantage,"
American Economic Review, American Economic Association, vol. 108(8), pages 2048-2087, August.
- Marika Cabral & Michael Geruso & Neale Mahoney, 2014. "Do Larger Health Insurance Subsidies Benefit Patients or Producers? Evidence from Medicare Advantage," NBER Working Papers 20470, National Bureau of Economic Research, Inc.
- Powell, David & Pacula, Rosalie Liccardo & Taylor, Erin, 2020.
"How increasing medical access to opioids contributes to the opioid epidemic: Evidence from Medicare Part D,"
Journal of Health Economics, Elsevier, vol. 71(C).
- David Powell & Rosalie Liccardo Pacula & Erin Taylor, 2015. "How Increasing Medical Access to Opioids Contributes to the Opioid Epidemic: Evidence from Medicare Part D," NBER Working Papers 21072, National Bureau of Economic Research, Inc.
- David Powell & Rosalie Liccardo Pacula & Erin Audrey Taylor, 2016. "How Increasing Medical Access to Opioids Contributes to the Opioid Epidemic Evidence from Medicare Part D," Working Papers WR-1169, RAND Corporation.
- Christopher C. Afendulis & Michael E. Chernew & Daniel P. Kessler, 2017. "The Effect of Medicare Advantage on Hospital Admissions and Mortality," American Journal of Health Economics, MIT Press, vol. 3(2), pages 254-279, Spring.
- Dasgupta, N. & Beletsky, L. & Ciccarone, D., 2018. "Opioid Crisis: No Easy Fix to Its Social and Economic Determinants," American Journal of Public Health, American Public Health Association, vol. 108(2), pages 182-186.
- Thomas C. Buchmueller & Colleen Carey, 2018.
"The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare,"
American Economic Journal: Economic Policy, American Economic Association, vol. 10(1), pages 77-112, February.
- Thomas C. Buchmueller & Colleen Carey, 2017. "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," NBER Working Papers 23148, National Bureau of Economic Research, Inc.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Mark Anderson, D. & Diris, Ron & Montizaan, Raymond & Rees, Daniel I., 2023.
"The effects of becoming a physician on prescription drug use and mental health treatment,"
Journal of Health Economics, Elsevier, vol. 91(C).
- Anderson, D. Mark & Diris, Ron & Montizaan, Raymond & Rees, Daniel I., 2021. "The Effects of Becoming a Physician on Prescription Drug Use and Mental Health Treatment," IZA Discussion Papers 14890, Institute of Labor Economics (IZA).
- D. Mark Anderson & Ron Diris & Raymond Montizaan & Daniel I. Rees, 2021. "The Effects of Becoming a Physician on Prescription Drug Use and Mental Health Treatment," NBER Working Papers 29536, National Bureau of Economic Research, Inc.
- Shishir Shakya & Collin Hodges, 2023. "Must‐access prescription drug monitoring programs and retail opioid sales," Contemporary Economic Policy, Western Economic Association International, vol. 41(1), pages 146-165, January.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Aliprantis, Dionissi & Fee, Kyle & Schweitzer, Mark E., 2023.
"Opioids and the labor market,"
Labour Economics, Elsevier, vol. 85(C).
- Dionissi Aliprantis & Mark E. Schweitzer, 2018. "Opioids and the Labor Market," Working Papers (Old Series) 1807, Federal Reserve Bank of Cleveland.
- Dionissi Aliprantis & Kyle Fee & Mark E. Schweitzer, 2019. "Opioids and the Labor Market," Working Papers 18-07R, Federal Reserve Bank of Cleveland.
- Dionissi Aliprantis & Kyle Fee & Mark E. Schweitzer, 2019. "Opioids and the Labor Market," Working Papers 18-07R3, Federal Reserve Bank of Cleveland, revised 14 Jul 2022.
- Laurence C. Baker & Kate Bundorf & Daniel Kessler, 2018. "The Effects of Medicare Advantage on Opioid Use," NBER Working Papers 25327, National Bureau of Economic Research, Inc.
- Shishir Shakya & Collin Hodges, 2023. "Must‐access prescription drug monitoring programs and retail opioid sales," Contemporary Economic Policy, Western Economic Association International, vol. 41(1), pages 146-165, January.
- Amy Finkelstein & Matthew Gentzkow & Dean Li & Heidi L. Williams, 2022. "What Drives Risky Prescription Opioid Use? Evidence from Migration," NBER Working Papers 30471, National Bureau of Economic Research, Inc.
- Chen, Chong & Huang, Qianqian & Shi, Chang & Yuan, Tao, 2024. "Opioid epidemic and corporate innovation," Journal of Corporate Finance, Elsevier, vol. 86(C).
- Johanna Catherine Maclean & Justine Mallatt & Christopher J. Ruhm & Kosali Simon, 2022.
"The Opioid Crisis, Health, Healthcare, and Crime: A Review of Quasi-Experimental Economic Studies,"
The ANNALS of the American Academy of Political and Social Science, , vol. 703(1), pages 15-49, September.
- Johanna Catherine Maclean & Justine Mallatt & Christopher J. Ruhm & Kosali I. Simon, 2022. "The Opioid Crisis, Health, Healthcare, and Crime: A Review Of Quasi-Experimental Economic Studies," NBER Working Papers 29983, National Bureau of Economic Research, Inc.
- Cornelius A. Rietveld & Pankaj C. Patel, 2021. "Prescription opioids and new business establishments," Small Business Economics, Springer, vol. 57(3), pages 1175-1199, October.
- Cornelius A. Rietveld & Pankaj C. Patel, 0. "Prescription opioids and new business establishments," Small Business Economics, Springer, vol. 0, pages 1-25.
- Ahomäki, Iiro & Pitkänen, Visa & Soppi, Aarni & Saastamoinen, Leena, 2020. "Impact of a physician-targeted letter on opioid prescribing," Journal of Health Economics, Elsevier, vol. 72(C).
- David Beheshti, 2019. "Adverse health effects of abuse‐deterrent opioids: Evidence from the reformulation of OxyContin," Health Economics, John Wiley & Sons, Ltd., vol. 28(12), pages 1449-1461, December.
- Daniele, Gianmarco & Le Moglie, Marco & Masera, Federico, 2023.
"Pains, guns and moves: The effect of the U.S. opioid epidemic on Mexican migration,"
Journal of Development Economics, Elsevier, vol. 160(C).
- Gianmarco Daniele & Marco Le Moglie & Federico Masera, 2020. "Pains, Guns and Moves: The Effect of the US Opioid Epidemic on Mexican Migration," BAFFI CAREFIN Working Papers 20141, BAFFI CAREFIN, Centre for Applied Research on International Markets Banking Finance and Regulation, Universita' Bocconi, Milano, Italy.
- Christopher J. Ruhm, 2018. "Deaths of Despair or Drug Problems?," NBER Working Papers 24188, National Bureau of Economic Research, Inc.
- Yevgeniy Feyman & Steven D. Pizer & Austin B. Frakt, 2021. "The persistence of medicare advantage spillovers in the post‐Affordable Care Act era," Health Economics, John Wiley & Sons, Ltd., vol. 30(2), pages 311-327, February.
- Janssen, Aljoscha & Zhang, Xuan, 2020. "Retail Pharmacies and Drug Diversion during the Opioid Epidemic," Working Paper Series 1373, Research Institute of Industrial Economics.
- Bradley T. Shapiro, 2020. "Advertising in Health Insurance Markets," Marketing Science, INFORMS, vol. 39(3), pages 587-611, May.
- Mayank Aggarwal & Anindya S. Chakrabarti & Chirantan Chatterjee, 2023. "Movies, stigma and choice: Evidence from the pharmaceutical industry," Health Economics, John Wiley & Sons, Ltd., vol. 32(5), pages 1019-1039, May.
- Michael Geruso & Timothy Layton, 2020.
"Upcoding: Evidence from Medicare on Squishy Risk Adjustment,"
Journal of Political Economy, University of Chicago Press, vol. 128(3), pages 984-1026.
- Michael Geruso & Timothy Layton, 2015. "Upcoding: Evidence from Medicare on Squishy Risk Adjustment," NBER Working Papers 21222, National Bureau of Economic Research, Inc.
- Michele Fioretti & Hongming Wang, 2023.
"Performance Pay in Insurance Markets: Evidence from Medicare,"
The Review of Economics and Statistics, MIT Press, vol. 105(5), pages 1128-1144, September.
- Michele Fioretti & Hongming Wang, 2020. "Performance Pay in Insurance Markets: Evidence from Medicare," Working Papers 2020.03, International Network for Economic Research - INFER.
- Michele Fioretti & Hongming Wang, 2021. "Performance Pay in Insurance Markets: Evidence from Medicare," Post-Print hal-03791843, HAL.
- Michele Fioretti & Hongming Wang, 2021. "Performance Pay in Insurance Markets: Evidence from Medicare," SciencePo Working papers Main hal-03386584, HAL.
- Michele Fioretti & Hongming Wang, 2021. "Performance Pay in Insurance Markets: Evidence from Medicare," SciencePo Working papers Main hal-03791843, HAL.
- Michele Fioretti & Hongming Wang, 2021. "Performance Pay in Insurance Markets: Evidence from Medicare," SciencePo Working papers hal-03386584, HAL.
- Michele Fioretti & Hongming Wang, 2021. "Performance Pay in Insurance Markets: Evidence from Medicare," Working Papers hal-03386584, HAL.
- David Dranove & Christopher Ody & Amanda Starc, 2021.
"A Dose of Managed Care: Controlling Drug Spending in Medicaid,"
American Economic Journal: Applied Economics, American Economic Association, vol. 13(1), pages 170-197, January.
- David Dranove & Christopher Ody & Amanda Starc, 2017. "A Dose of Managed Care: Controlling Drug Spending in Medicaid," NBER Working Papers 23956, National Bureau of Economic Research, Inc.
- Baicker, Katherine & Chernew, Michael E. & Robbins, Jacob A., 2013.
"The spillover effects of Medicare managed care: Medicare Advantage and hospital utilization,"
Journal of Health Economics, Elsevier, vol. 32(6), pages 1289-1300.
- Katherine Baicker & Michael Chernew & Jacob Robbins, 2013. "The Spillover Effects of Medicare Managed Care: Medicare Advantage and Hospital Utilization," NBER Working Papers 19070, National Bureau of Economic Research, Inc.
More about this item
Keywords
Medicare advantage; Opioid use;Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:jhecon:v:70:y:2020:i:c:s0167629619304758. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/inca/505560 .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.